Cancer cells do not develop acquired resistance to COTI-2 unlike treatment with paclitaxel and cisplatin.

<p>A549 NSCLC (A), DMS-153 SCLC (B) and SHP-77 SCLC (C) cells were cultured in IC₅₀ concentrations of COTI-2, paclitaxel, or cisplatin for 4 rounds of treatment (5 generations of cells including the parental cells). The surviving 50% of cells from the initial IC₅₀ tested were harvested and cultured for 5 days, after which time this new generation of cells was re-treated with the same agent and a new IC₅₀ value was established. Emerging resistance was identified by increasing IC₅₀ values in successive generations. Significant differences were assessed by Student’s <i>t</i>-test (<i>p</i><0.05). *Significantly different from parental cells treated with the mentioned drug. Data points indicate the mean from 3 independent experiments ± SEM.